These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24531207)

  • 1. FDA faces regulatory challenges with new approaches to medicine.
    Roehr B
    BMJ; 2014 Feb; 348():g1530. PubMed ID: 24531207
    [No Abstract]   [Full Text] [Related]  

  • 2. US FDA outreach to the regenerative medicine community: challenges and opportunities.
    Whittlesey KJ; Witten C
    Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010.
    Mason C; Manzotti E
    Regen Med; 2010 May; 5(3):307-13. PubMed ID: 20455641
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluating the FDA regenerative medicine framework: opportunities for stakeholders.
    Richardson E; Akkas F; Master Z
    Regen Med; 2020 Jul; 15(7):1825-1832. PubMed ID: 32815780
    [No Abstract]   [Full Text] [Related]  

  • 5. Cell Therapy Regulatory Toolkit: an online regulatory resource.
    Culme-Seymour EJ; Davies JL; Hitchcock J; Mason J; Carpenter MK; Mason C
    Regen Med; 2015; 10(5):531-4. PubMed ID: 26237697
    [No Abstract]   [Full Text] [Related]  

  • 6. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 7. Balancing Safety and Innovation for Cell-Based Regenerative Medicine.
    Marks P; Gottlieb S
    N Engl J Med; 2018 Mar; 378(10):954-959. PubMed ID: 29514023
    [No Abstract]   [Full Text] [Related]  

  • 8. The Center for Devices and Radiological health: an update.
    Donawa M
    Med Device Technol; 2001 Dec; 12(10):24, 26-7. PubMed ID: 15966141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revising the Regulation of Stem Cell-Based Therapies: Critical Assessment of Potential Models.
    von Tigerstrom B
    Food Drug Law J; 2015; 70(2):315-37, iii. PubMed ID: 26302602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What ails the FDA?
    Marcus DM
    N Engl J Med; 2005 Jun; 352(24):2554. PubMed ID: 15962405
    [No Abstract]   [Full Text] [Related]  

  • 13. Muddied messages about FDA.
    Miller HI
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract]   [Full Text] [Related]  

  • 14. Manufacturing challenges in regenerative medicine.
    Martin I; Simmons PJ; Williams DF
    Sci Transl Med; 2014 Apr; 6(232):232fs16. PubMed ID: 24739757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory science as culture: contested two-dimensional values at the US FDA.
    Abraham J
    Sci Cult (Lond); 2002 Sep; 11(3):309-35. PubMed ID: 15971364
    [No Abstract]   [Full Text] [Related]  

  • 16. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The government's role in advancing regenerative medicine and tissue engineering - science, safety, and ethics.
    Smith DS
    Periodontol 2000; 2006; 41():16-29. PubMed ID: 16686924
    [No Abstract]   [Full Text] [Related]  

  • 18. Beyond biotechnology: FDA regulation of nanomedicine.
    Miller J
    Columbia Sci Technol Law Rev; 2003; 4():E5. PubMed ID: 15977335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What ails the FDA?
    Cohen FJ
    N Engl J Med; 2005 Jun; 352(24):2554. PubMed ID: 15962406
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
    Phillips KA; Van Bebber SL
    Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.